Table 6.
Baseline features of the population of patients after propensity score-matching (n = 90) who underwent endoscopic ultrasound-guided gastroenterostomy (n = 45) or enteral stenting (n = 45).
| Variables | EUS-GE n = 45 |
ES n = 45 |
p Value ° |
|---|---|---|---|
| Age (years), mean ± SD | 68.9 ± 11.5 | 70.0 ± 10.0 | 0.523 |
| Sex Male Female |
18 (40.0%) 27 (60.0%) |
21 (46.7%) 24 (53.3%) |
0.670 |
| PS-ECOG 0–1 2 3–4 |
25 (55.6%) 13 (28.9%) 7 (15.6%) |
23 (51.1%) 19 (42.2%) 3 (6.7%) |
0.281 |
| Charlson Comorbidity Index ≤7 >7 |
27 (60.0%) 18 (40.0%) |
30 (66.7%) 15 (33.3%) |
0.662 |
| Pre-procedural GOOSS * 0 1 |
18 (40.0%) 27 (60.0%) |
25 (55.6%) 20 (44.4%) |
0.205 |
| Type of malignancy Pancreatic Other |
30 (66.7%) 15 (33.3%) |
37 (82.2%) 8 (17.8%) |
0.147 |
| Stage of disease Resectable/locally advanced Metastatic |
22 (48.9%) 23 (51.1%) |
24 (53.3%) 21 (46.7%) |
0.123 |
| Ascites No Yes |
42 (93.3%) 3 (6.7%) |
44 (97.8%) 1 (2.2%) |
0.616 |
| Biliary obstruction No Yes |
19 (42.2%) 26 (57.8) |
22 (48.9%) 23 (51.1%) |
0.672 |
| Stenosis location ** Type I Type II Type III |
12 (26.7%) 19 (42.2%) 14 (31.1%) |
13 (28.9%) 20 (44.4%) 12 (26.7%) |
0.935 |
| Follow-up duration, median (IQR), days | 80 (52–174) | 99 (41.5–192) | 0.316 |
EUS-GE: endoscopic ultrasound-guided gastroenterostomy; ES: enteral stenting; SD: standard deviation; PS-ECOG: Eastern Cooperative Oncology Group performance status; GOOSS: gastric outlet obstruction score system. ° ES vs. EUS-GE. * According to Adler and Baron [23]; ** According to the Mutignani classification [26].